证券日报网讯众生药业9月10日在互动平台回答投资者提问时表示，公司高度重视药品的国外市场机 会，将适时开展昂拉地韦片海外市场的拓展，探索更多可能性，加快国际化推进步伐。公司正推进该产 品的商业化工作，围绕学术生态构建、数据化服务升级及关键项目实践三大维度深化营销创新，持续拓 展多种销售渠道和提高市场占有率。 （文章来源：证券日报） ...

（编辑 王雪儿） 证券日报网讯 众生药业9月9日在互动平台回答投资者提问时表示，ZSP1601片是具有全新作用机制的治 疗代谢功能障碍相关脂肪性肝炎（MASH）的一类创新药，为国家重大新药创制项目，该项目正在开展 IIb期临床试验。公司高度重视药品的国外市场机会，积极寻求国际合作。如达到相关披露标准，公司 将严格根据信息披露规则及时履行信息披露义务。 ...

（编辑 王雪儿） 证券日报网讯 众生药业9月9日在互动平台回答投资者提问时表示，公司按照"中药为基、创新引领，聚 焦特色的医药健康企业"的战略目标定位，专注主业，努力提升业绩，并重视自身价值提升和股东价值 回报，切实保障中小投资者的权益。如有相关计划，公司将依据信息披露规则履行信息披露责任。 ...

（文章来源：每日经济新闻） 众生药业（002317.SZ）9月9日在投资者互动平台表示，ZSP1601片是具有全新作用机制的治疗代谢功 能障碍相关脂肪性肝炎（MASH）的一类创新药，为国家重大新药创制项目，该项目正在开展IIb期临 床试验。公司高度重视药品的国外市场机会，积极寻求国际合作。如达到相关披露标准，公司将严格根 据信息披露规则及时履行信息披露义务。 每经AI快讯，有投资者在投资者互动平台提问：贵公司的zsp-1601新药的临床进展情况如何？是否顺 利，目前该药物有国外的公司感兴趣和贵公司洽谈BD合作么？ ...

众生药业(002317) 公司研究/公司点评 昂拉地韦上市，创新药管线快速推进 ——众生药业（002317.SZ）2025 年半年报点评 ◼ 事件 公司发布 2025 年半年报，上半年公司实现营业收入 13.0 亿元（同比- 4.74%，下同）。归母净利润 1.88 亿元（+114.96%），扣非归母净利润 为 1.87 亿元（+7.42%）。2025 年二季度公司实现营业收入 6.65 亿元（- 7.99%）。归母净利润 1.05 亿元（+191.52%），扣非归母净利润为 1.08 亿元（+6.58%）。 中成药是公司核心业务基础与重要业绩增长来源 分产品来看，上半年中成药销售收入 6.89 亿元（-10.14%），化学药销 售收入 4.95 亿元（+6.10%）。其中，中成药是公司核心业务基础与重 要业绩增长来源，上半年中成药毛利率达 69.57%（+ 0.46pct），其核 心产品复方血栓通系列制剂、脑栓通胶囊在慢病治疗领域持续拓展， 与舒肝益脾系列制剂、固肾合剂等产品形成多元协同。 昂拉地韦片上市，核心管线进展顺利 创新药中已有昂拉地韦片（抗成人甲流）和来瑞特韦片（抗新冠）两 款产品获批上市，昂拉地 ...

众生药业（002317.SZ）9月8日在投资者互动平台表示，RAY1225注射液已收到美国食品药品监督管理 局签发的药物临床试验批准通知书，同意 RAY1225注射液直接在美国开展超重或肥胖适应症的II期临床 试验。公司积极寻求国际合作，组织开展国际多中心II期临床研究，争取早日完成相关研究，申报药物 上市，为广大患者提供更多治疗选择。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问公司的RAY1225在国外的临床进展如何？预计什 么时候完成二期入组？ ...

证券之星消息，9月5日中药板块较上一交易日上涨0.99%，ST香雪领涨。当日上证指数报收于3812.51， 上涨1.24%。深证成指报收于12590.56，上涨3.89%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300147 | ST香雪 | 11.24 | 10.41% | 30.51万 | | 3.27亿 | | 600329 | 达仁堂 | 45.91 | 3.89% | 8.49万 | | 3.83亿 | | 833266 | 生物谷 | 11.57 | 3.30% | 4.80万 | | 5513.26万 | | 002317 | 众生药业 | 20.59 | 3.05% | 29.45万 | | 5.93亿 | | 836433 | 大唐药业 | 7.33 | 2.81% | 5.00万 | | 3639.42万 | | 002287 | 奇正藏药 | 27.50 | 2.80% | 5.28万 | | 1.43亿 | | 00059 ...

8月28日晚，众生药业发布2025年半年报，交出了一份超出市场预期的成绩单。报告期内，公司实现营 收13亿元，归母净利润1.88亿元，同比高增114.96%；扣非净利润1.87亿元，同比增长7.42%。这一业绩 表现标志着公司已迎来明确的业绩拐点，核心业务韧性与创新药放量形成共振，推动业绩大幅回暖，展 现出从传统中药企业向创新药龙头转型的显著成效。 业绩拐点确立：利润倍增凸显发展质效 众生药业上半年业绩呈现"营收保持平稳，利润大幅提升"的良好态势，营收保持稳定的同时，净利润实 现翻倍增长，彰显了公司经营质量的显著提升。这一业绩表现超出市场预期，主要得益于公司"中药基 本盘+创新药突破"双轮驱动战略的有效实施。 中成药是众生药业的业务基石，也是其持续进行战略升级的源头活水。其核心产品复方血栓通系列制 剂、脑栓通胶囊在慢病治疗领域的持续拓展，舒肝益脾系列制剂、固肾合剂等符合慢病治疗需求的产品 的持续放量，逐渐形成了公司在慢病治疗领域的特色，为公司的长期增长奠定了基础。随着中成药集采 风险逐渐出清，该板块有望实现稳健增长，贡献稳定现金流。2025年上半年，公司中成药产品收入6.89 亿元，占总收入比例的53.03% ...

Core Viewpoint - The stock of Zhongsheng Pharmaceutical has experienced fluctuations, with a year-to-date increase of 72.05%, but a recent decline of 3.56% over the last five trading days [1] Financial Performance - For the first half of 2025, Zhongsheng Pharmaceutical reported revenue of 1.3 billion yuan, a year-on-year decrease of 4.74%, while net profit attributable to shareholders increased by 114.96% to 188 million yuan [2] - The company has distributed a total of 2.019 billion yuan in dividends since its A-share listing, with 502 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for Zhongsheng Pharmaceutical was 89,900, a decrease of 1.32% from the previous period, with an average of 8,470 circulating shares per shareholder, an increase of 1.33% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the fourth largest shareholder with 9.1731 million shares, a new addition, while other significant shareholders have reduced their holdings [3] Market Activity - On September 3, 2023, Zhongsheng Pharmaceutical's stock price was 20.56 yuan per share, with a trading volume of 2.32 billion yuan and a turnover rate of 1.46% [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent net purchase of 181 million yuan on July 29 [1] Business Overview - Zhongsheng Pharmaceutical, established on December 31, 2001, and listed on December 11, 2009, is primarily engaged in the research, production, and sales of pharmaceuticals, with 96.13% of its revenue coming from pharmaceutical manufacturing [1]

Investment Rating - The investment rating for the biotechnology industry is "Positive" (maintained) [1] Core Insights - The small molecule GLP-1RA market is expected to provide new incremental space for weight loss and diabetes management, with significant interest from multinational corporations (MNCs) accelerating their involvement in this sector [7][25] - The leading product in the small molecule GLP-1RA space is Orforglipron from Eli Lilly, which has completed multiple global Phase III clinical trials and is positioned to submit a New Drug Application (NDA) in the second half of 2025 [25][26] - Domestic companies are making substantial progress in the small molecule GLP-1RA pipeline, with several candidates entering late-stage clinical trials, indicating strong potential for commercialization and international expansion [19][25] Summary by Sections 1. Development Prospects of Small Molecule GLP-1RA - Oral GLP-1 drugs offer advantages such as ease of use and high patient compliance, with over 75% of initial treatment patients preferring daily oral therapy [14] - The small molecule GLP-1RA market is characterized by low costs and flexibility in usage scenarios, with significant recent business development (BD) transactions [14][23] 2. MNCs Accelerating Small Molecule GLP-1RA Pipeline - Eli Lilly's Orforglipron is the fastest progressing small molecule GLP-1RA product globally, with three Phase III trials achieving primary endpoints [25][27] - Other major pharmaceutical companies like AstraZeneca and Roche are also advancing their small molecule GLP-1RA pipelines, with several candidates in Phase II trials [29][30] 3. Pharmacokinetic Characteristics Impacting Efficacy - Pharmacokinetic features are crucial for the efficacy of small molecule GLP-1RA, with companies exploring new formulations to enhance solubility and absorption [6][19] 4. Investment Recommendations - The report recommends several companies as potential beneficiaries in the small molecule GLP-1RA space, including Innovent Biologics, East China Pharmaceutical, and others, highlighting their strong clinical development and commercialization potential [7][19]